Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $4.26 Million - $5.1 Million
12,424 New
12,424 $5.06 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $207,691 - $244,789
-938 Closed
0 $0
Q4 2021

Feb 16, 2022

BUY
$177.01 - $223.45 $166,035 - $209,596
938 New
938 $206,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Benchmark Investment Advisors LLC Portfolio

Follow Benchmark Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benchmark Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Benchmark Investment Advisors LLC with notifications on news.